Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL).
- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL).
- This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform.
- “enVista Envy is the next step in the dramatic transformation of our IOL portfolio,” said Luc Bonnefoy, president, Global Surgical, Bausch + Lomb.
- Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets, including the U.S. and Europe.